Siah2 Ubiquitin Ligase in Immune Checkpoint and Melanomagenesis
Abstract
This application focuses on melanoma, the deadliest form of skin cancer, which is one of the military relevance focus areas for the FY17 PRCRP. The proposed studies are expected to advance our understanding of the regulation of melanoma growth by immune checkpoint controls. Our coordinated and focused studies will establishSiah2 as a novel therapeutic modality in the tumor immunity space. Given the genetic, biochemical, immunological, and cell biological data we have obtained so far, there is a strong likelihood that the work will significantly accelerate progress towards the design of more effective treatments for melanoma using immune checkpoint approaches. Specifically, the work will identify Siah substrates that control immune cell components and could be exploited to enhance targeting of melanoma, thus enabling a more efficient therapy. These findings will guide new strategies for the treatment and monitoring of melanoma.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2020
- Accession Number
- AD1128353
Entities
People
- Zeev Ronai
Organizations
- Sanford Burnham Prebys Medical Discovery Institute